In July 2008, it was announced that Access Pharmaceuticals would acquire publicly held drug delivery firm MacroChem using the porceeds from sale of its some of own shares of its common stock. In September 2005, Macrochem Corporation (NASDAQ:MCHM) had announced it would end its research and auction off all of its assets. Macrochem had been working in the field of transdermal drug-delivery systems which allow drugs to be absorbed through the skin via creams, gels, patches, and the like. MacroChem ihad been trying to attract business partners by applying its SEPA (Soft Enhancer of Percutaneous Absorption) system to FDA-approved drugs. The company did test its system's use with drugs used to treat impotence (Topiglan), testosterone deficiency, arthritis pain, and skin conditions. MacroChem also developed a delivery with potential applications in cosmetics and other topical products (moisturizers, sunscreens, insect repellents). Ascent Pediatrics has licensed SEPA for possible use in treating allergies and respiratory disorders.
